Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
![]() |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
1291 | AEG 3482 | JNK inhibitor | €90.00 | |
4217 | AS-703026 | Potent, selective and orally bioavailable small molecular inhibitor of MEK1/2 | Inquire | |
2179 | ASK1 Inhibitor 10 | Potent, selective, and orally bioavailable ASK1 inhibitor | €130.00 | |
1516 | AZD6244 | MEK1 and MEK2 inhibitor | €60.00 | |
1999 | AZD8330 | MEK 1 inhibitor | €105.00 | |
2002 | Bentamapimod | JNK inhibitor, which inhibited JNK1, JNK2 and JNK3 | €70.00 | |
1358 | BIRB 796 | MAPK inhibitor (p38 specific) | €65.00 | |
1809 | BIX 02189 | MEK5 inhibitor; ERK5 inhibitor | €110.00 | |
3346 | BIX02188 | Potent MEK5 inhibitor | €110.00 | |
1808 | BIX02188-Me | MEK5 inhibitor; ERK5 inhibitor | €110.00 | |
2856 | BMS 582949 | Inhibitor of p38α MAPK | €155.00 | |
2025 | CC-401 | ATP-competitive JNK inhibitor | €120.00 | |
2634 | CC-930 | Potent, selective, and orally active anti-fibrotic JNK inhibitor | €95.00 | |
1694 | FR 180204 | ERK inhibitor; AP-1 inhibitor | €95.00 | |
3741 | GDC-0994 | ERK1/2 inhibitor | Inquire | |
1761 | GSK 1120212 | MEK1 and MEK2 inhibitor | €70.00 | |
3059 | GW 284543 hydrochloride | Selective MEK5 inhibitor | €95.00 | |
2361 | JNK-IN-8 | Remarkably potent and selective covalent inhibitor of JNK | €95.00 | |
1895 | LY 2228820 | Inhibitor of p38 MAPK | €105.00 | |
3893 | LY-3214996 | Orally bioavailable, potent and highly selective inhibitor of ERK1 and ERK2 | Inquire | |
2366 | NG 25 trihydrochloride | Type II inhibitor of TAK1 (MAP3K7) and MAP4K2 (GCK) | €75.00 | |
1814 | NQDI 1 | Inhibitor of apoptosis signal-regulating kinase 1 (ASK1) | €115.00 | |
1408 | PD0325901 | MEK1 and MEK2 inhibitor | €50.00 | |
1365 | PD169316 | MAPK inhibitor (p38 specific) | €95.00 | |
1368 | PD184352 | MEK 1 inhibitor | €80.00 | |
1223 | PD98059 | MEK inhibitor | €80.00 | |
2107 | PF 431396 | Dual FAK(PTK2) and PYK2 inhibitor | €80.00 | |
4215 | PF-562271 | Potent, selective, ATP-competitive and reversible dual FAK/PYK2 inhibitor | €110.00 | |
1837 | PH 797804 | Inhibitor of p38α MAPK | €115.00 | |
1364 | SB 202190 | MAPK inhibitor (p38 specific) | €95.00 |